Expression of Stress Markers During Meth Treatment (EXPRESS+)

Status unconfirmed · Not applicable

Conditions studied: Substance-Related Disorders, HIV

In brief

This is a non-randomized behavioral trial that aims to investigate whether changes in inflammatory and type I IFN expression coincide with changes in methamphetamine use and viral load over the course of 12 weeks in HIV-positive people assigned male at birth with and without methamphetamine use disorder.

Key facts

Study ID

NCT05558345

Run by

University of California, Los Angeles

People needed

55

Starts

2022-09-01

Expected to finish

2026-03-31

Last updated by the study team

2024-05-07

Who can join

Age: 18 and older, up to 45. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• For Contingency Management:
• Assigned male sex at birth
• 18 to 45 years of age
• Reports having sex with men in the past 12 months.
• HIV-positive (confirmed by certification or by HIV rapid test)
• Has an HIV care provider (last seen in the past 12 months)
• Has a current antiretroviral prescription
• Meets the DSM-5 criteria for methamphetamine use disorder using SCID-5
• Urine test is positive for methamphetamine within 30 days of their screening visit
• Seeking treatment for methamphetamine use disorder.
• Ability to attend twice weekly appointments for drug testing and treatment
• For Non-substance-using Control:
• Assigned male sex at birth
• 18 to 45 years of age
• Reports having sex with men in the past 12 months.
• HIV-positive (confirmed by certification or by HIV rapid test)
• Has an HIV care provider (last seen in the past 12 months)
• Has a current antiretroviral prescription

You may not qualify if…

• For Contingency Management:
• Identifies as (cis- or transgender) female
• Reports another current or past substance use disorder
• Reports being in another intervention or clinical trial for substance use
• Positive test for opioids, cocaine, and/or MDMA
• For Non-substance-using Control:
• Identifies as (cis- or transgender) female
• Positive test for methamphetamine, opioids, cocaine, and/or MDMA.
• Reports substance use (methamphetamine, opioids, cocaine, MDMA, hallucinogens, heavy alcohol use, and/or tobacco) in the past 6 months
• Reports past or current substance use disorder

Where it is running

• UCLA Vine Street Clinic — Los Angeles, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.